Drug Trial Radar · NCT06953869
Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia
Last checked: Nov 19, 2026Latest source record: Jun 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
420
Planned (sponsor's estimate)
Start
Apr 21, 2025
Primary completion
Nov 2027
Study completion Jan 2028
Sponsor
- Lead sponsor
- Vanda PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- May 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, double-blind, randomized study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon and matching placebo in male and female pediatric participants with insomnia disorder.
Conditions
- Insomnia Disorder
Interventions
Tasimelteon Oral SuspensionDrug
Single daily dose, weight-based liquid suspension formulation.
PlaceboDrug
Placebo comparator.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in sleep latency, as measured by daily sleep diary.Time frame: 12 Weeks
Locations
35 sites in 4 countries. Site status is shown where the registry gives one.
Vanda Investigational Site
Dothan, Alabama · Recruiting
Vanda Investigational Site
Phoenix, Arizona · Recruiting
Vanda Investigational Site
Irvine, California · Recruiting
Vanda Investigational Site
Miami, Florida · Recruiting
Vanda Investigational Site
Miami Lakes, Florida · Recruiting
Vanda Investigational Site
Winter Park, Florida · Recruiting
Vanda Investigational Site
Snellville, Georgia · Recruiting
Vanda Investigational Site
Stockbridge, Georgia · Recruiting
Vanda Investigational Site
Naperville, Illinois · Recruiting
Vanda Investigational Site
Worcester, Massachusetts · Recruiting
Vanda Investigational Site
Great Falls, Montana · Recruiting
Vanda Investigational Site
Lincoln, Nebraska · Active not recruiting
Vanda Investigational Site
Las Vegas, Nevada · Recruiting
Vanda Investigational Site
Cleveland, Ohio · Recruiting
Vanda Investigational Site
Columbia, South Carolina · Recruiting
Vanda Investigational Site
Myrtle Beach, South Carolina · Recruiting
Vanda Investigational Site
Nashville, Tennessee · Recruiting
Vanda Investigational Site
Houston, Texas · Recruiting
Vanda Investigational Site
Plano, Texas · Recruiting
Vanda Investigational Site
San Antonio, Texas · Recruiting
Vanda Investigational Site
San Antonio, Texas · Recruiting
Vanda Investigational Site
Berlin, Germany · Recruiting
Vanda Investigational Site
Leipzig, Germany · Recruiting
Vanda Investigational Site
Bydgoszcz, Poland · Recruiting
Vanda Investigational Site
Gdansk, Poland · Recruiting
Vanda Investigational Site
Krakow, Poland · Recruiting
Vanda Investigational Site
Poznan, Poland · Recruiting
Vanda Investigational Site
Wroclaw, Poland · Recruiting
Vanda Investigational Site
Great Yarmouth, United Kingdom · Recruiting
Vanda Investigational Site
Leicester, United Kingdom · Recruiting
Vanda Investigational Site
Liverpool, United Kingdom · Recruiting
Vanda Investigational Site
London, United Kingdom · Recruiting
Vanda Investigational Site
London, United Kingdom · Recruiting
Vanda Investigational Site
London, United Kingdom · Recruiting
Vanda Investigational Site
Sheffield, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.